CGON: Durable efficacy, operational simplicity, and pivotal trial catalysts drive strong outlook
Key highlights include robust BLA progress for cretostimogene grenadenorepvec, strong differentiation through durable efficacy and operational simplicity, and a well-capitalized position supporting multiple clinical and commercial milestones. Near-term catalysts include pivotal trial data and label…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.